[A26-98] Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A26-31
Last updated 03.09.2026
Project no.:
A26-98
Commission:
Commission awarded on 28.07.2026 by the Federal Joint Committee (GBA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with metastatic hormone-sensitive prostate cancer (mHSPC) and breast cancer-associated gene (BRCA)1/2 mutations (germline and/or somatic)
Result of dossier assessment:
- Patients with newly diagnosed high-risk mHSPC and BRCA1/2 mutations (germline and/or somatic): unchanged after addendum: added benefit not proven
- All other patients in the therapeutic indication: unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-98
| Project no. | Title | Status |
|---|---|---|
| A26-31 | Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
03-09-2026 A G-BA decision was published.
G-BA documents on this decision